Paraneoplastic encephalitis: clinically based approach on diagnosis and management.

Adult neurology Neurological oncology Neuropathology

Journal

Postgraduate medical journal
ISSN: 1469-0756
Titre abrégé: Postgrad Med J
Pays: England
ID NLM: 0234135

Informations de publication

Date de publication:
30 06 2023
Historique:
received: 23 03 2022
accepted: 25 04 2022
medline: 3 7 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: ppublish

Résumé

Paraneoplastic neurological syndromes (PNSs) comprise a subset of immune-mediated nervous system diseases triggered by an underlying malignancy. Each syndrome usually shows a distinct clinical presentation and outcome according to the associated neural antibodies. PNSs generally have a subacute onset with rapid progression and severe neurological disability. However, some patients may have hyperacute onset or even show chronic progression mimicking neurodegenerative diseases. Updated diagnostic criteria for PNS have been recently established in order to increase diagnostic specificity and to encourage standardisation of research initiatives related to PNS. Treatment for PNS includes oncological therapy and immunomodulation to halt neurological deterioration although current treatment options are seldom effective in reversing disability. Nevertheless, growing knowledge and better understanding of PNS pathogenesis promise better recognition, earlier diagnosis and novel treatment strategies. Considering that PNSs provide a model of effective anticancer immunity, the impact of these studies will extend far beyond the field of neurology.

Identifiants

pubmed: 37389581
pii: 7211539
doi: 10.1136/postgradmedj-2022-141766
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

669-678

Subventions

Organisme : French National Research Agency

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Postgraduate Medical Journal.

Auteurs

Mantas Vaišvilas (M)

Department of Neuro-oncology Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.

Nicolás Lundahl Ciano-Petersen (NL)

Department of Neuro-oncology Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.

M D Macarena Villagrán-García (MD)

Department of Neuro-oncology Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.

Sergio Muñiz-Castrillo (S)

Department of Neuro-oncology Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.

Alberto Vogrig (A)

Department of Neuro-oncology Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.

Jérôme Honnorat (J)

Department of Neuro-oncology, Université Claude Bernard Lyon 1 Villeurbanne, Lyon, France.
Department of Neuro-oncology, Hospices Civils de Lyon, Bron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH